Clinical Translation

Neuroimaging biomarkers that infer proteinopathy in sporadic cases could broaden eligibility and improve FTD trial efficiency. The article frames the findings as support for moving from static speech biomarkers toward dynamical-systems representations in computational psychiatry. Treatments targeting internal human biology must pass regulatory requirements, safety testing, and clinical trials. External clinical speech datasets and longitudinal settings are identified as important directions for further research. The approach is described as having been tested against at least one endogenous target in animals. Sufficient longitudinal data across trials is expected to make microbiota-outcome correlations statistically meaningful. Many disease-modifying FTD trials recruit people with known genetic mutations to increase pathological certainty within cohorts. The article rejects the idea that any medical treatment can be claimed to be completely safe. Current FTD trials are challenged by clinical and pathological overlap, which impairs stratification and treatment-effect assessment. Genotype-based trial recruitment improves cohort homogeneity but excludes many sporadic FTD patients. Cl…